Next Article in Journal
Next Article in Special Issue
Previous Article in Journal
Previous Article in Special Issue
Toxins 2011, 3(4), 409-419; doi:10.3390/toxins3040409
Article

A Comparison of the Anti-Tumor Effects of a Chimeric versus Murine Anti-CD19 Immunotoxins on Human B Cell Lymphoma and Pre-B Acute Lymphoblastic Leukemia Cell Lines

,
,
 and *
Received: 3 March 2011; in revised form: 30 March 2011 / Accepted: 30 March 2011 / Published: 6 April 2011
(This article belongs to the Special Issue Immunotoxins)
View Full-Text   |   Download PDF [469 KB, updated 7 April 2011; original version uploaded 6 April 2011]
Abstract: Precursor B cell acute lymphoblastic leukemia (pre-B ALL) affects five to six thousand adults and almost three thousand children every year. Approximately 25% of the children and 60% of the adults die from their disease, highlighting the need for new therapies that complement rather than overlap chemotherapy and bone marrow transplantation. Immunotherapy is a class of therapies where toxicities and mechanisms of action do not overlap with those of chemotherapy. Because CD19 is a B cell- restricted membrane antigen that is expressed on the majority of pre-B tumor cells, a CD19-based immunotherapy is being developed for ALL. In this study, the anti-tumor activities of immunotoxins (ITs) constructed by conjugating a murine monoclonal antibody (MAb), HD37, or its chimeric (c) construct to recombinant ricin toxin A chain (rRTA) were compared both in vitro using human pre-B ALL and Burkitt’s lymphoma cell lines and in vivo using a disseminated human pre-B ALL tumor cell xenograft model. The murine and chimeric HD37 IT constructs were equally cytotoxic to pre-B ALL and Burkitt’s lymphoma cells in vitro and their use in vivo resulted in equivalent increases in survival of SCID mice with human pre-B ALL tumors when compared with control mice.
Keywords: chimerization; anti-CD19; ricin A chain chimerization; anti-CD19; ricin A chain
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Tsai, L.K.; Pop, L.M.; Liu, X.; Vitetta, E.S. A Comparison of the Anti-Tumor Effects of a Chimeric versus Murine Anti-CD19 Immunotoxins on Human B Cell Lymphoma and Pre-B Acute Lymphoblastic Leukemia Cell Lines. Toxins 2011, 3, 409-419.

AMA Style

Tsai LK, Pop LM, Liu X, Vitetta ES. A Comparison of the Anti-Tumor Effects of a Chimeric versus Murine Anti-CD19 Immunotoxins on Human B Cell Lymphoma and Pre-B Acute Lymphoblastic Leukemia Cell Lines. Toxins. 2011; 3(4):409-419.

Chicago/Turabian Style

Tsai, Lydia K.; Pop, Laurentiu M.; Liu, Xiaoyun; Vitetta, Ellen S. 2011. "A Comparison of the Anti-Tumor Effects of a Chimeric versus Murine Anti-CD19 Immunotoxins on Human B Cell Lymphoma and Pre-B Acute Lymphoblastic Leukemia Cell Lines." Toxins 3, no. 4: 409-419.



Toxins EISSN 2072-6651 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert